 Home > Active Ingredient News > Blood System > Blood: All-trans retinoic acid + low-dose rituximab in the treatment of refractory/relapsed immune thrombocytopenia

Blood: All-trans retinoic acid + low-dose rituximab in the treatment of refractory/relapsed immune thrombocytopenia

 Last Update: 2021-12-01
 Source: Internet
 Author: User

Tags

gasoline skin effects

adverse effects oxygen therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and lack of platelet production

immunity

This study aims to compare the effects of all-trans retinoic acid (ATRA) combined with low-dose rituximab (LD-RTX) and LD-RTX monotherapy in patients with corticosteroid refractory or recurrent immune thrombocytopenia Efficacy and safety

To compare the efficacy and efficacy of all-trans retinoic acid (ATRA) combined with low-dose rituximab (LD-RTX) and LD-RTX monotherapy in patients with corticosteroid refractory or relapsed immune thrombocytopenia safety

The recruited test patients were randomly (2:1) divided into two groups: 112 patients received LD-RTX combined with ATRA treatment, and 56 patients received LD-RTX monotherapy

Relapse-free survival rate of patients in the two treatment groups

The overall response rate of the LD-RTX combined with ATRA group was higher than that of the LD-RTX single-agent group (80% vs 59%; difference between groups: 0.

The overall response rate of the LD-RTX combined with ATRA group was higher than that of the LD-RTX single-agent group .

All-trans retinoic acid combined with low-dose rituximab can significantly improve the overall remission rate and sustained remission rate of patients with hormone refractory or recurrent immune thrombocytopenia, suggesting that the combination therapy may become such refractory Potential options for patients

Original source:

Yejun Wu, et al.

All-trans retinoic acid plus low- dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.